openPR Logo
Press release

Despite Progress Injectable/Infusible Antimetabolites Remain the Workhorse in Cancer Treatments

12-29-2016 01:29 PM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The world of oncology continues to evolve as physician specialists and researchers apply the latest knowledge and therapies to treat patients afflicted with cancer. Several advances have prolonged survival and provided hope to patients and their loved ones. Targeted drugs - typically monoclonal antibodies that bind to a specific cell surface receptor to affect a therapeutic response – have produced many success stories in treating a number of important cancers while sparing the patient from harsh chemotherapeutic agents.

A strong dose of optimism is well-justified, but while progress continues to be made the majority of oncology cases will continue to rely on traditional chemotherapy for the foreseeable future. These agents – primarily antimetabolites and alkylating agents – have been the workhorse of therapeutic oncology for decades. They are effective in slowing the uncontrolled cell growth that is the hallmark of cancer, but because they work more-or-less indiscriminately they are difficult on patients.

Antimetabolites work by replacing natural substances as building blocks in DNA molecules, thereby altering the function of enzymes required for cell metabolism and protein synthesis. Because the therapeutic action of antimetabolites relies in interference with DNA (and to a lesser degree RNA) synthesis, their action is highly cell cycle specific. While there are several drug classes that comprise the population of antimetabolites the majority can be grouped as purine, pyrimidine or folate analogs.

Including derivatives, there are currently fifteen antimetabolites approved by the FDA. If approved dosages are included, there are 197 unique injectable antimetabolite drug products across twenty-nine suppliers. This segment is highly concentrated with the top eight suppliers accounting for 62 percent of all products.

The ability of antimetabolites to interfere with normal cell division has created increasing interest in methods to protect both caregiver and patient from corollary exposure during the chemotherapy administration process. These efforts have spawned a new subclass of drug reconstitution and delivery devices collectively referred to as closed drug transfer systems.

Injectable and infusible antimetabolites are detailed in a new and comprehensive report researched and written by Greystone Research Associates. Injectable/Infusible Antimetabolites: Products, Markets and Opportunities analyzes injectable and infusible antimetabolite products, their indications, demand drivers and market activity. The report includes analysis of competitive factors, market trends and economic factors, and provides profiles of sector participants.

More information is available at http://www.greystoneassociates.org

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 0301 USA
Voice: 603-595-4340
Fax: 603-218-7020
www.greystoneassociates.org

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Despite Progress Injectable/Infusible Antimetabolites Remain the Workhorse in Cancer Treatments here

News-ID: 402729 • Views: 193

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases


More Releases for Amherst

Intradermal Drug Delivery Gaining Momentum as Technology and Benefits Converge
(Amherst, NH) – Evolution in drug delivery device design is changing the way a growing number of therapeutic substances are administered. This trend is being fostered by the desire by patients for more user friendly methods for self-medicating, and by the need for safer, more reliable drug products that improve compliance. For drugs capable of being administered across the skin, intradermal delivery is viewed as an approach that addresses these
New Aircraft Designs Creating Opportunities for High Performance Aerospace Coati …
(Amherst, NH) – As aerospace manufacturers and their engineering teams push the design envelope to create aircraft with better fuel efficiency and lower maintenance requirements, they are relying increasingly on engineered materials for a growing list of structural and non-structural elements and components. This trend is changing the way aircraft are developed, produced and maintained. It’s also presenting opportunities for specialty materials suppliers with products that can improve production
Evolution in Markets for Radiation Curable Coatings Creating Risks and Opportuni …
(Amherst, NH) – Recent advances in materials and equipment are creating new demand for radiation curable coatings in a number of industrial applications. This new demand is occurring as several technology advances are being brought into the marketplace. By removing some of the key limitations of radcure coatings, these advances are enabling radcure coatings to meet unique application requirements, opening up a number of new opportunities. Technical advances that are having
Drug Delivery Coatings Creating Opportunities for Developers and Practitioners
(Amherst, NH) – Advances in coating technology have given rise to a new generation of coating formulations that can reliably deliver therapeutic substances from the surface of an implanted medical device. In currently approved products, these devices provide a primary function, with the drug contributing therapeutic benefit that improves patient outcomes. Currently more than two dozen companies are pursuing specialty coatings capable of delivering APIs. These participants are exploring a
Adros Energy Expands Clean Energy Business with Energy Audit Services and opens …
Adros Energy; a leading green energy company in New England, announced today that they are opening a new headquarters in Amherst, NH after a successful 1st year of operation in the renewable energy market. The company was founded in January of 2009 and has found success during the incubation period of the company. The infrastructure building of the company in 2009 includes: • Revenue generation from its solar PV,
Esensors Adds New Websensor Features
July 22, 2008 – Amherst, NY – EM01B Websensor is an environmental sensor that provides accurate measurement of temperature, relative humidity and light over a network. This month, Esensors adds some new features to EM01B Websensor. The free Websensor Data Logger now enables users to easily export the data to other software tools for analysis. This allows the flexibility to generate custom data views and make data collection more